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Septal myectomy: cut, coil, or boil?
Mario Togni, Michael Billinger, Stephane Cook, and Otto M. Hess*
Swiss Cardiovascular Center, University Hospital Inselspital, Freiburgstrasse, CH-3010 Berne, Switzerland
This editorial refers to ‘Non-surgical septal myocardial
reduction by coil embolization for hypertrophic obstruc-
tive cardiomyopathy: early and 6 months follow-up’ by
E. Durand et al.,† on page 348
Hypertrophic cardiomyopathy (HOCM) is characterized by asym-
metric septal hypertrophy with outflow tract obstruction in
approximately one-third of patients. However, recent studies
suggest that obstruction may be present in up to 70% of patients
with enhanced sympathetic activation under exercise conditions.1
Clinical features are dyspnoea on exertion, angina pectoris, and
atrial and ventricular arrhythmias, which mainly are due to diastolic
dysfunction, whereas syncope and presyncope often are due to
outflow tract obstruction and represent an ominous sign of ventri-
cular arrhythmias and sudden cardiac death.
The treatment strategy is 3-fold: (i) medical therapy for targeting
diastolic dysfunction; (ii) myectomy (interventional or surgical) for
relief of obstruction; and (iii) implantable defibrillators for preven-
tion of sudden cardiac death.2
For decades, the gold standard for septal myectomy has been
surgical treatment, with excellent short- and long-term results.3
In 1995, a new interventional technique (alcohol ablation of
the septum) was put forward for percutaneous treatment of
HOCM.4 In their study, Durand and co-workers5 propose a new
technique for septal ablation of the myocardium, namely coiling
of septal branches. One to five coils were deployed into the first
or second septal branch of the left anterior descending artery in
20 patients with HOCM, thereby inducing septal ischaemia with
myocardial necrosis and a consecutive creatine kinase (CK) rise
of 386 U/L. As a result, the pressure gradient decreased signifi-
cantly from 80 to 35 mmHg at the 6 months follow-up examin-
ation. Clinical symptoms and exercise capacity improved, as
reflected by a significant increase in peak oxygen consumption
(from 14.8+ 4.5 to 18.5+ 4.5 ml/kg/min) and a prolongation of
exercise duration (from 7.1+3.5 to 9.0+3.8 min). The pro-
cedure was well tolerated, and no AV blocks were observed.
However, in one patient, septal perforation occurred, which was
surgically treated; however, the patient died postoperatively.
Other complications were not reported, and the authors claim
from this series that in contrast to alcohol ablation or surgical
myectomy, no AV blocks occur with coil embolization. Nevertheless,
they suggest that larger studies, ideally employing a randomized
comparison between coil embolization and alcohol septal ablation,
are warranted.
The authors are to be congratulated for these results and this
new technique. A major limitation of alcohol ablation is, indeed,
an AV block, which occurs in 27% of all patients (transient);
10% need pacemaker implantation (Table 1). However, previous
data suggest that infarct size is larger with alcohol ablation (10–
15 g) compared with 3 g with coil embolization. This finding is par-
alleled by a larger CK rise with alcohol ablation (1038 U/L) when
compared with coil embolization (386 U/L). Alcohol appears to
penetrate more deeply into the septal region and induces a
larger area of necrosis, whereas coil embolization leads primarily
to ischaemia and only secondarily to necrosis. However, in some
rare cases, alcohol dissipation (spill over) to non-target myocardial
areas (right ventricle or apex of the left ventricle) may occur.
In Durand et al.’s pilot study, a quarter of the patients had unsuc-
cessful treatment with a resting gradient .50 mmHg at 6 months.
This reflects the learning curve, as stated by the authors, or indi-
cates the less aggressive nature of the technique. Alcohol ablation
has been reported to be successful in 90–95% of all patients.
As an alternative, radiofrequency ablation has been rec-
ommended for reduction of septal hypertrophy in children with
HOCM, because alcohol ablation in this patient group is strongly
discouraged due to the induction of potential arrhythmias.6 From
reviewing the literature and comparing alcohol ablation with coil
embolization (Table 1), there are clear differences in the release
of CK and the decrease in outflow tract gradient, suggesting a
larger infarct with alcohol ablation than with coil embolization.
The absence of AV block with coil embolization could be explained
by the smaller infarct size and the modest decrease in pressure
gradient.
Interestingly enough, a Polish group7 performing coil emboliza-
tion in patients with HOCM reported a transient AV block in
43% of patients (Table 1). Thus, Durand’s study may represent a
highly selected group that does not show AV block during coil
embolization. Larger samples may answer this question.
Only a randomized trial will allow for a fair comparison of the
two techniques. A contraindication for alcohol ablation (and an
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indication for coil embolization) may represent pre-existing left
bundle branch block (LBBB). A complete AV block may occur in
these patients when alcohol ablation induces right bundle branch
block (RBBB) in up to 50% of patients. Amiodarone treatment is
another contraindication due to associated AV conduction pro-
longation. A third contraindication to alcohol ablation is the pre-
existing AV block I or II (Figure 1).
In summary, coil embolization represents a new and promising
method for reducing septal hypertrophy in patients with HOCM.
The first results suggest a lower risk for the occurrence of AV
block during septal ablation, but haemodynamic success may be
limited, with less reduction in outflow tract gradient.
Conflict of interest: none declared.
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Table 1 A comparison of alcohol ablation and coil embolization
Author Year n
AV block
PM Death (cardiac) Peak CK (U/L)
LVOTG resting (mmHg)
Transient Permanent Before After
Alcohol ablation
Chang8 2003 224 N/A 14% – – 1335 62 20
Osterne9 2003 18 44% 11% 11% 5.5% – 68 3.8
Chang10 2004 173 16% – – – 1387 58 19
Gietzen11 2004 146 N/A 11% 25% 2.5% 508 52 14
Talreja12 2004 58 N/A 12% 12% – – 72 11
Faber13 2005 242 N/A 10% 10% 1.2% 483 57 25
Fernandes14 2005 130 N/A 13% 13% 1.5% 1676 74 4
Streit15 2007 24 21% 13% 13% 0% 931 38 13
Total or mean 1015 27% 12% 14% 2% 1038 60 17
Coil embolization
Iacob7 2004 7 43% 0% 0% 0% N/A 72 34
Durand5 2007 28 0% 0% 0% 4% 386 80 35
Total or mean 35 9% 0% 0% 3% 386 78 35
N/A, not available; PM, pacemaker, CK, creatine kinase; LVOTG, left ventricular outflow tract gradient.
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